FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896564305> ?p ?o ?g. }

• W2896564305 endingPage "662" @default.
• W2896564305 startingPage "652" @default.
• W2896564305 abstract "Cabozantinib is a multitargeted tyrosine kinase inhibitor that demonstrated remarkable responses on bone scan in metastatic prostate cancer. Randomized trials failed to demonstrate statistically significant overall survival (OS). We studied the dynamics of biomarker changes with imaging and biopsies pretherapy and posttherapy to explore factors that are likely to be predictive of efficacy with cabozantinib.Experimental Design: Eligibility included patients with metastatic castrate-resistant prostate cancer with normal organ function and performance status 0-2. Cabozantinib 60 mg orally was administered daily. Pretherapy and 2 weeks post, 99mTc-labeled bone scans, positron emission tomography with 18F-sodium fluoride (NaF-PET) and 18F-(1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) thymine (FMAU PET) scans were conducted. Pretherapy and posttherapy tumor biopsies were conducted, and serum and urine bone markers were measured.Twenty evaluable patients were treated. Eight patients had a PSA decline, of which 2 had a decline of ≥50%. Median progression-free survival (PFS) and OS were 4.1 and 11.2 months, respectively, and 3 patients were on therapy for 8, 10, and 13 months. The NaF-PET demonstrated a median decline in SUVmax of -56% (range, -85 to -5%, n = 11) and -41% (range, -60 to -25%, n = 9) for patients who were clinically stable and remained on therapy for ≥4 or <4 cycles, respectively. The FMAU PET demonstrated a median decline in SUVmax of -44% (-60 to -14%) and -42% (-63% to -23%) for these groups. The changes in bone markers and mesenchymal epithelial transition/MET testing did not correlate with clinical benefit.Early changes in imaging and tissue or serum/urine biomarkers did not demonstrate utility in predicting clinical benefit with cabozantinib therapy." @default.
• W2896564305 created "2018-10-26" @default.
• W2896564305 creator A5000198604 @default.
• W2896564305 creator A5004764119 @default.
• W2896564305 creator A5018597938 @default.
• W2896564305 creator A5039968524 @default.
• W2896564305 creator A5044158880 @default.
• W2896564305 creator A5044208310 @default.
• W2896564305 creator A5050077770 @default.
• W2896564305 creator A5055577800 @default.
• W2896564305 creator A5070483633 @default.
• W2896564305 creator A5072203753 @default.
• W2896564305 creator A5073593424 @default.
• W2896564305 date "2019-01-15" @default.
• W2896564305 modified "2023-09-27" @default.
• W2896564305 title "Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer" @default.
• W2896564305 cites W1910380884 @default.
• W2896564305 cites W1968024679 @default.
• W2896564305 cites W1979055605 @default.
• W2896564305 cites W2017058268 @default.
• W2896564305 cites W2019607817 @default.
• W2896564305 cites W2021198987 @default.
• W2896564305 cites W2023642977 @default.
• W2896564305 cites W2024001437 @default.
• W2896564305 cites W2024928163 @default.
• W2896564305 cites W2025361602 @default.
• W2896564305 cites W2038308707 @default.
• W2896564305 cites W2046409949 @default.
• W2896564305 cites W2066964592 @default.
• W2896564305 cites W2081084828 @default.
• W2896564305 cites W2081438275 @default.
• W2896564305 cites W2100945326 @default.
• W2896564305 cites W2101083650 @default.
• W2896564305 cites W2104945673 @default.
• W2896564305 cites W2134975411 @default.
• W2896564305 cites W2141454098 @default.
• W2896564305 cites W2145920882 @default.
• W2896564305 cites W2158011521 @default.
• W2896564305 cites W2161306413 @default.
• W2896564305 cites W2162827359 @default.
• W2896564305 cites W2165088640 @default.
• W2896564305 cites W2167331614 @default.
• W2896564305 cites W2286152207 @default.
• W2896564305 cites W2325709854 @default.
• W2896564305 cites W2341714825 @default.
• W2896564305 cites W2471050799 @default.
• W2896564305 cites W2507638513 @default.
• W2896564305 cites W2522176514 @default.
• W2896564305 cites W2595997004 @default.
• W2896564305 cites W2603879439 @default.
• W2896564305 cites W2737968130 @default.
• W2896564305 cites W2754785828 @default.
• W2896564305 cites W2760071114 @default.
• W2896564305 cites W2781525129 @default.
• W2896564305 doi "https://doi.org/10.1158/1078-0432.ccr-18-1473" @default.
• W2896564305 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6335157" @default.
• W2896564305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30327304" @default.
• W2896564305 hasPublicationYear "2019" @default.
• W2896564305 type Work @default.
• W2896564305 sameAs 2896564305 @default.
• W2896564305 citedByCount "4" @default.
• W2896564305 countsByYear W28965643052020 @default.
• W2896564305 countsByYear W28965643052023 @default.
• W2896564305 crossrefType "journal-article" @default.
• W2896564305 hasAuthorship W2896564305A5000198604 @default.
• W2896564305 hasAuthorship W2896564305A5004764119 @default.
• W2896564305 hasAuthorship W2896564305A5018597938 @default.
• W2896564305 hasAuthorship W2896564305A5039968524 @default.
• W2896564305 hasAuthorship W2896564305A5044158880 @default.
• W2896564305 hasAuthorship W2896564305A5044208310 @default.
• W2896564305 hasAuthorship W2896564305A5050077770 @default.
• W2896564305 hasAuthorship W2896564305A5055577800 @default.
• W2896564305 hasAuthorship W2896564305A5070483633 @default.
• W2896564305 hasAuthorship W2896564305A5072203753 @default.
• W2896564305 hasAuthorship W2896564305A5073593424 @default.
• W2896564305 hasBestOaLocation W28965643051 @default.
• W2896564305 hasConcept C121608353 @default.
• W2896564305 hasConcept C126322002 @default.
• W2896564305 hasConcept C126894567 @default.
• W2896564305 hasConcept C143998085 @default.
• W2896564305 hasConcept C2780192828 @default.
• W2896564305 hasConcept C2781064419 @default.
• W2896564305 hasConcept C71924100 @default.
• W2896564305 hasConceptScore W2896564305C121608353 @default.
• W2896564305 hasConceptScore W2896564305C126322002 @default.
• W2896564305 hasConceptScore W2896564305C126894567 @default.
• W2896564305 hasConceptScore W2896564305C143998085 @default.
• W2896564305 hasConceptScore W2896564305C2780192828 @default.
• W2896564305 hasConceptScore W2896564305C2781064419 @default.
• W2896564305 hasConceptScore W2896564305C71924100 @default.
• W2896564305 hasFunder F4320332161 @default.
• W2896564305 hasIssue "2" @default.
• W2896564305 hasLocation W28965643051 @default.
• W2896564305 hasLocation W28965643052 @default.
• W2896564305 hasLocation W28965643053 @default.
• W2896564305 hasLocation W28965643054 @default.
• W2896564305 hasLocation W28965643055 @default.
• W2896564305 hasLocation W28965643056 @default.

• next